Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03611738 · ClinicalTrials.gov registry record · Phase 1

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

A Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Active
Registry status
Phase 1
Development phase
21
Enrollment target
2
Study locations

NCT03611738 is a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 21 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03611738, a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
21 participants
Enrollment target
2
Study locations

Study Summary

The main purpose of this study is to find out what effects (good and bad) ceritinib (Zykadia®) used in combination with docetaxel (Taxotere®) will have on participants and their cancer. The results will help to determine the best safe dose of the combination of the medications Ceritinib (Zykadia®) and docetaxel (Taxotere®) and to find out if this combination of drugs will help people that have this type of Non-small Cell Lung Cancer (NSCLC).

Conditions Studied

Non-Small Cell Lung Cancer Lung Cancer Stage IV Non-small Cell Lung Cancer Non Small Cell Lung Cancer Metastatic Non-Small Cell Lung Cancer Stage IIIB EGFR Negative Non-Small Cell Lung Cancer

Interventions

  • DRUG Docetaxel
  • DRUG Ceritinib

Study Locations (2)

Florida

  • Advent Health Orlando - Orlando
  • H. Lee Moffitt Cancer Center and Research Institute - Tampa

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2019-02-01
Est. Completion 2026-04
Phase Phase 1

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

502 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03611738

The ClinicalTrials.gov registry entry for NCT03611738 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.

NCT03611738 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT03611738 about?

NCT03611738 is a clinical study titled "Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC". The main purpose of this study is to find out what effects (good and bad) ceritinib (Zykadia®) used in combination with docetaxel (Taxotere®) will have on participants and their cancer. The results will help to determine the best safe dose of the combination of the medications Ceritinib (Zykadia®) a...

What is the current status of trial NCT03611738?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2019-02-01. Estimated completion is 2026-04.

What conditions does trial NCT03611738 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Stage IV Non-small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer Stage IIIB.

What interventions are being tested in trial NCT03611738?

The interventions under investigation include: Docetaxel (DRUG), Ceritinib (DRUG).

Who is sponsoring clinical trial NCT03611738?

This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03611738 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Lung Cancer

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.